以兹提米比
医学
他汀类
动脉硬化
PCSK9
内科学
可欣
心脏病学
血压
前蛋白转化酶
血脂谱
脂蛋白
药理学
胆固醇
内分泌学
低密度脂蛋白受体
作者
Andromachi Reklou,Niki Katsiki,Asterios Karagiannis,Vasilios G. Athyros
出处
期刊:Current Vascular Pharmacology
[Bentham Science]
日期:2019-12-18
卷期号:18 (1): 38-42
被引量:10
标识
DOI:10.2174/1570161117666190121102323
摘要
Arterial stiffness (AS) is considered an independent predictor of cardiovascular disease (CVD) events. Among lipid lowering drugs, statins have a beneficial effect on AS, independent of their hypolipidaemic effect. Based on 3 meta-analyses and other studies, this effect is compound- and doserelated. Potent statins at high doses are more effective than less powerful statins. Ezetimibe (± statin) also seems to decrease AS in patients with dyslipidaemia. Fibrates have no effect on AS. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have data that beneficially affect all AS risk factors, suggesting a beneficial effect on artery compliance. However, there is no direct measurement of their effect on AS indices. In patients with dyslipidaemia, prescribing high dose statins (± ezetimibe) will not only decrease low-density lipoprotein cholesterol levels but also improve AS (in addition to other effects). This effect on AS may contribute to the observed reduction in vascular events.
科研通智能强力驱动
Strongly Powered by AbleSci AI